October 27, 2016: Following an unexpected setback of Bristol-Myers Squibb’s Opdivo as a as a monotherapy for a “broad patient population” in patients with untreated advanced non-small cell lung cancer, the company plans to undergo a reorganization of its R&D unit.
October 27, 2016: Genomic company 23andMe has halted its plans to develop a new gene-sequencing program that would have allowed customers to learn more about potential predisposition to genetic diseases.
October 27, 2016: Investors got their chance to dive a little deeper into Biogen’s finances at its third-quarter conference call yesterday. Despite a pop in the stock value, there are other factors that make Biogen seem like a company in pause mode waiting for something to happen.
October 27, 2016: Allergan continues to build up its pipeline through a string of acquisitions. This time the company struck a $200M deal to snag Motus Therapeutics in an effort to shore up its gastrointestinal therapies.